The adjunctive role of antiphospholipid antibodies in systemic lupus erythematosus cardiac involvement

Clinical and Experimental Rheumatology

Volumn 24, Issue 3, 2006, Pages 287-294

  Amoroso, Antonio ^a   Cacciapaglia, Fabio ^b   De Castro, Stefano ^a   Battagliese, Alessandro ^a   Coppolino, Giusy ^b   Galluzzo, Sara ^b   Vadacca, Marta ^b   Afeltra, Antonella ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Antiphospholipid antibodies; Systemic lupus erythematosus; Transthoracic echocardiography; Valvular heart disease

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; CORTICOSTEROID; CYCLOSPORIN A; CYTOTOXIC AGENT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; LUPUS ANTICOAGULANT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDIC ACID; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY;

ADOLESCENT; ADULT; AGED; AORTA VALVE REGURGITATION; ARTICLE; ATHEROSCLEROSIS; CARDIOMEGALY; CARDIOVASCULAR RISK; CAUCASIAN; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART DILATATION; HEART DISEASE; HEART LEFT ATRIUM; HEART VENTRICLE SEPTUM; HUMAN; MALE; MITRAL VALVE REGURGITATION; MORBIDITY; PERICARDIAL EFFUSION; PREVALENCE; PRIORITY JOURNAL; PULMONARY VALVE INSUFFICIENCY; RISK MANAGEMENT; SCREENING TEST; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE REGURGITATION; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ECHOCARDIOGRAPHY; FEMALE; HEART VALVE DISEASES; HUMANS; ITALY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

EID: 33746646726     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. DORIA A, IACCARINO L, SARZI-PUTTINI P, ATZENI F, TURRIEL M, PETRI M: Cardiac involvement in systemic lupus erythematosus. Lupus 2005; 14: 683-6.
2. WILSON WA, GHARAVI AE, KOIKE T et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
3. MIYAKIS S, LOCKSHIN MD, ATSUMI T et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 Feb; 4: 295-306.
4. LEVINE JS, BRANCH DW, RAUCH J: The antiphospholipid syndrome. N Engl J Med 2002 Mar 7; 346: 752-63
5. MICHELOUD D, SANCHEZ-RAMON S, CARBONE J et al.: Discordance between antibeta2-glycoprotein-I and anti-cardiolipin antibodies in patients with clinical criteria of antiphospholipid syndrome. Clin Exp Rheumatol 2005; 23: 525-8.
6. SHOENFELD Y: Systemic antiphospholipid syndrome. Lupus 2003; 12: 497-8.
7. HOJNIK M, GEORGE J, ZIPOREN L, SHOENFELD Y: Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996 Apr 15; 93: 1579-87.
8. MARAI I, TINCANI A, BALESTRIERI G, SHOENFELD Y: Anticardiolipin and antibeta-2-glycoprotein I antibodies. Autoimmunity 2005; 38: 33-8.
9. BERTOLACCINI ML, GOMEZ S, PASCUAL-PAREJA JF et al.: Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis 2005; 64: 1639-43.
10. KHAMASHTA MA, CERVERA R, ASHERSON RA et al.: Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 1990; 335: 1541-4.
11. BOUILLANNE O, MILLAIRE A, de GROOTE P et al.: Prevalence and clinical significance of antiphospholipid antibodies in heart valve disease: a case-control study. Am Heart J 1996; 132: 790-5.
12. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982 Nov; 25: 1271-7.
13. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
14. TRIPODI A, CHANTARANGKUL V, CLERICI M, MANNUCCI PM: Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. Thromb Haemost 2002; 88: 583-6.
15. HENRY WL, DEMARIA A, GRAMIAK R et al.: Report of the American Society of Echocardiography: nomenclature and standards in two-dimensional echocardiography. Circulation 1980; 62: 212-7.
16. ZILE MR, BRUTSAERT DL: New concepts in diastolic dysfunction and diastolic heart failure: part I & part II. Circulation 2002; 105: 1387-1393 & 1503-8.
17. HARRIS EN, PIERANGELI SS: Revisiting the anticardiolipin test and its standardization. Lupus 2002; 11: 269-75.
18. HARRIS EN: Special report. The Second International Anticardiolipin Standardization Worshop/The Kingston Antiphospholipid Antibody Study (KAPS) group. Am J Clin Pathol 1990; 94: 476-84.
19. HARRIS EN, PIERANGELI S, BIRCH D: Anticardiolipin wet workshop report. Fifth International Symposium on antiphospholipid antibodies. Am J Clin Pathol 1994; 101: 616-24.
20. BRANDT JT, TRIPLETT DA, ALVING B, SCHARRER I: Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-90.
21. ONG ML, VEERAPEN K, CHAMBERS JB, LIM MN, MANIVASAGAR M, WANG F: Cardiac abormalities in systemic lupus erythematosus: prevalence and relationship to disease activity. Int J Cardiol 1992; 34: 69-74.
22. NIHOYANNOPOULOS P, GOMEZ PM, JOSHI J, LOIZOU S, WALPORT MJ, OAKLEY CM: Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 1990; 82: 369-75.
23. CERVERA R, FONT J, PARE C et al.: Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis 1992; 51: 156-9.
24. VIANNA JL, KHAMASHTA MA, ORDI-ROS J et al.: Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med 1994 Jan; 96: 3-9.
25. NESHER G, ILANY J, ROSENMANN D, ABRAHAM AS: Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 1997; 27: 27-35.
26. FORD SE, KENNEDY L, FORD PM: Clinicopathologic correlations of antiphospholipid antibodies: an autopsy study. Arch Pathol Lab Med 1994; 118: 491-5.
27. LIE JT: Vasculitis in the antiphospholipid syndrome: culprit or consort? J Rheumatol 1994; 21: 397-8.
28. ZIPOREN L, GOLDBERG I, ARAD M et al.: Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 1996; 5: 196-205.
29. SHAPIRO RF, GAMBLE CN, WIESNER KB et al.: Immunopathogenesis of Libman-Sacks endocarditis: assessment by light and immunofluorescent microscopy in two patients. Ann Rheum Dis 1977; 36: 508-16.
30. JOUHIKAINEN T, POHJOLA-SINTONEN S, STEPHANSSON E: Lupus anticoagulant and cardiac manifestations in systemic lupus erythematosus. Lupus 1994; 3: 167-72.
31. ROMAN MJ, SALMON JE, SOBEL R et al.: Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol 2001; 87: 663-6.
32. SIPEK-DOLNICAR A, HOJNIK M, BOZIC B, VIZJAK A, ROZMAN B, FERLUGA D: Clinical presentations and vascular histopathology in autopsied patients with systemic lupus erythematosus and anticardiolipin antibodies. Clin Exp Rheumatol 2002; 20: 335-42.
33. AMITAL H, LANGEVITZ P, LEVY Y et al.: Valvular deposition of antiphospholipid antibodies in the antiphospholipid syndrome: a clue to the origin of the disease. Clin Exp Rheumatol 1999; 17: 99-102.
34. ASHERSON RA, LUBBE WF: Cerebral and valve lesions in SLE: association with antiphospholipid antibodies. J Rheumatol 1988; 15: 539-43.
35. GARCIA-TORRES R, AMIGO MC, de la ROSA A, MORON A, REYES PA: Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings. Lupus 1996; 5: 56-61.
36. LEV S, SHOENFELD Y: Cardiac valvulopathy in the antiphospholipid syndrome. Clin Rev Allergy Immunol 2002; 23: 341-8.
37. TOUBI E, KRAUSE I, FRASER A et al.: Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 2005; 23: 499-504.
38. CARRERAS LO, FORASTIERO RR, MARTINUZZO ME: Which are the best biological markers of the antiphospholipid syndrome? J Autoimmun 2000; 15: 163-72.
39. AMOROSO A, MITTERHOFER AP, DEL PORTO F et al.: Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus. Hum Immunol 2003; 64: 265-73.
40. EVANGELOPOULOS ME, ALEVIZAKI M, TOUMANIDIS S et al.: Mitral valve prolapse in systemic lupus erythematosus patients: clinical and immunological aspect. Lupus 2003; 12: 308-11.
41. PETRI M: Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000; 9: 170-5.
42. MOSS KE, IOANNOU Y, SULTAN SM, HAQ I, ISENBERG DA: Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002; 61: 409-13.